News

January 20, 2011
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results

WALTHAM, Mass., Jan 20, 2011 (BUSINESS WIRE) --

ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m. ET on Thursday, January 27, 2011, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2010 - the second quarter of the Company's 2011 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0379. Passcode: 7227748. The call also may be accessed through the Investor Information section of the Company's website, http://www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 3, 2011.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen's collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.

SOURCE: ImmunoGen, Inc.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
Executive Director, Investor Relations and Corporate Communications
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?